Last reviewed · How we verify
M2RLAB 001
At a glance
| Generic name | M2RLAB 001 |
|---|---|
| Also known as | Autologous Leukocyte Cells |
| Sponsor | M2RLAB SL |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Modified Autologous Leukocyte Cells for the Treatment of Acute Kidney Injury After Cardiac Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M2RLAB 001 CI brief — competitive landscape report
- M2RLAB 001 updates RSS · CI watch RSS
- M2RLAB SL portfolio CI